---
title: "Cambium Bio Director Increases Stake Through Share Placement"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280261825.md"
description: "Cambium Bio Limited's director, Yu-Hung Sebastian Tseng, has increased his stake through a share placement, acquiring 4,363,637 shares via Zheng Yang Biomedical Technology Limited, raising its total to 10,862,136 shares. Tseng's direct holding remains unchanged. This move indicates strengthened insider alignment with the company's future. The latest analyst rating for Cambium Bio (AU:CMB) is a Hold with a price target of A$0.46. The company operates in the biotechnology sector, focusing on advanced biomedical technologies, with a current market cap of A$13.12M."
datetime: "2026-03-24T05:47:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280261825.md)
  - [en](https://longbridge.com/en/news/280261825.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280261825.md)
---

# Cambium Bio Director Increases Stake Through Share Placement

### Claim 30% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Regeneus Ltd. ( (AU:CMB) ) has provided an update.

Cambium Bio Limited has disclosed a change in director Yu-Hung Sebastian Tseng’s interests following a recent share placement. Tseng, who holds shares directly and through Zheng Yang Biomedical Technology Limited, increased his indirect holding as part of the company’s capital-raising activities.

Under the transaction, Zheng Yang Biomedical Technology Limited acquired 4,363,637 ordinary shares at $0.55 each, lifting its stake to 10,862,136 shares, while Tseng’s direct holding remained unchanged. The acquisition, issued via a placement announced in January 2026, consolidates Tseng’s exposure to Cambium Bio and signals strengthened insider alignment with the company’s future performance.

The most recent analyst rating on (AU:CMB) stock is a Hold with a A$0.46 price target. To see the full list of analyst forecasts on Regeneus Ltd. stock, see the AU:CMB Stock Forecast page.

**More about Regeneus Ltd.**

Cambium Bio Limited, formerly associated with Regeneus Ltd., operates in the biotechnology and biomedical sector. The company’s activities involve advanced biomedical technologies, with equity holdings including stakes held through Zheng Yang Biomedical Technology Limited, reflecting a capital structure typical of clinical- and research-focused biotechs.

**Average Trading Volume:** 11,883

**Technical Sentiment Signal:** Sell

**Current Market Cap:** A$13.12M

Learn more about CMB stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [CMBM.US](https://longbridge.com/en/quote/CMBM.US.md)
- [CMBMF.US](https://longbridge.com/en/quote/CMBMF.US.md)

## Related News & Research

- [Frontier Energy Limited (FHE) Receives a Buy from Bell Potter](https://longbridge.com/en/news/294788237.md)
- [Macquarie Sticks to Their Hold Rating for GQG Partners, Inc. Shs Chess Depository Interests Repr 1 Sh (GQG)](https://longbridge.com/en/news/294768314.md)
- [Ginkgo Bioworks partners with Acies Bio to license Aspergillus niger strains for protein production](https://longbridge.com/en/news/294697896.md)
- [Pfizer (NYSE:PFE) Issues Quarterly Earnings Results](https://longbridge.com/en/news/294844585.md)
- [Exousia Bio Nearing Completion of Milestone Multimillion-Dollar Capital Investment | LMMY Stock News](https://longbridge.com/en/news/294843709.md)